Indegene Ltd (INDGN) — shareholding pattern, promoter holding, financials and share price
About Indegene Ltd (INDGN)
Indegene Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as INDGN and on the BSE under scrip code 544172. Its ISIN is INE065X01017.
Incorporated in 1998, Indegene Ltd provides solutions consisting of analytics, technology and commercial, medical, regulatory and safety services to life science and health care organizations [1]
Indegene Limited is a digital-first life sciences commercialization company, specializing in biopharmaceutical, biotech, and medical device sectors. It combines healthcare domain knowledge with technology to enhance product development and marketing.
The company achieved a significant financial milestone in Q3 FY26 by surpassing $100 million in quarterly revenue for the first time, reflecting over 30% YoY growth.
Listed peers in Healthcare Research, Analytics & Technology: Syngene International Ltd, Suven Life Sciences Ltd, Vimta Labs Ltd, Take Solutions Ltd, Bilcare Ltd, Jeevan Scientific Technology Ltd.
Valuation & Returns
10 Jul 2026At ₹508.4 a share on 10 Jul 2026, Indegene Ltd (INDGN) was valued at a price-to-earnings ratio of 30.54x against an industry P/E of 61.73x and a price-to-book of 4.68x on a book value of ₹108.55 per share as of Mar 2025. Solomo computes return on equity of 15.33% and return on capital employed of 20.03% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 30.54x
- Industry P/E
- 61.73x
- P/B
- 4.68x
- EPS (TTM)
- ₹16.65
- Book value / share
- ₹108.55
- ROE
- 15.33%
- ROCE
- 20.03%
- ROA
- 12.06%
- Debt / equity
- 0.04x
- Dividend yield
- 0.39%
- EBITDA margin
- 19.11%
- 52-week range
- ₹414.9 – ₹596.5
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Indegene Ltd (INDGN) reported revenue of ₹3,510 crore, net profit of ₹401 crore and earnings per share of ₹16.65. That compares with revenue of ₹2,839 crore and net profit of ₹407 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1,003 crore and net profit ₹80 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 1,665 | 2,306 | 2,590 | 2,839 | 3,510 |
| Net profit (₹ cr) | 163 | 266 | 337 | 407 | 401 |
| EPS (₹) | 937.73 | 11.99 | 15.14 | 16.95 | 16.65 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 26.73% | 9.34% | 9.64% |
| Profit growth | 46.57% | 10.96% | 20.79% |
| Stock price CAGR | - | - | -12% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 0% of Indegene Ltd (INDGN) (unchanged from the previous quarter), foreign institutional investors (FII) hold 9.91% and domestic institutional investors (DII) hold 8.74%. Market capitalisation was ₹12,250 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2024.
Largest disclosed public shareholders in Jun 2026: Nadathur Fareast Pte Ltd 21.87%, Manish Gupta 8.91%, Rajesh Bhaskaran Nair 7.14%, Bpc Genesis Fund I Spv Ltd 5.75%, Sanjay S Parikh 4.98%, Bpc Genesis Fund I A Spv Ltd 2.98%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 0% | - | 9.91% | 8.74% | 100% |
| Mar 2026 | 0% | - | 10.27% | 8.3% | 100% |
| Dec 2025 | 0% | - | 11.48% | 8.07% | 100% |
| Sep 2025 | 0% | - | 11.3% | 6.96% | 100% |
| Jun 2025 | 0% | - | 10.05% | 7.2% | 100% |
| Mar 2025 | 0% | - | 5.24% | 4.96% | 100% |
| Dec 2024 | 0% | - | 5.03% | 3.98% | 100% |
| Sep 2024 | 0% | - | 4.82% | 3.17% | 100% |